Histamine-2 receptor antagonists and gastric cancer.
We conducted a case-control study at Group Health Cooperative of Puget Sound to evaluate the relation between longterm histamine-2 (H2) receptor antagonist use and gastric cancer. We identified 113 cases and 452 controls and estimated a relative risk (RR) of 2.0 [95% confidence interval (C1) = 1.0-3.9]. When we evaluated the effect of time-since-first-use, the RR estimates were 6.5, 1.2, and 1.0 for 2-4 years of use, 5-9 years, and > or = 10 years, respectively. The data provide substantial evidence that long-term H2 antagonist use is not associated with gastric cancer.
Johnson
A G
AG
Department of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.
Jick
S S
SS
Perera
D R
DR
Jick
H
H
D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002927:Cimetidine / Q000009:adverse effects*; D005260:Female; D006635:Histamine H2 Antagonists / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011899:Ranitidine / Q000009:adverse effects*; D012044:Regression Analysis; D012189:Retrospective Studies; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D014861:Washington / Q000453:epidemiology
D006635:Histamine H2 Antagonists; D002927:Cimetidine; D011899:Ranitidine